Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.6 USD | -0.75% | +3.44% | -44.32% |
05-15 | Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-22 | HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.32% | 612M | |
+8.04% | 113B | |
+10.27% | 106B | |
+0.41% | 22.27B | |
-12.06% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-6.05% | 17.24B | |
+7.41% | 14.29B | |
+36.94% | 12.52B |
- Stock Market
- Equities
- CABA Stock
- News Cabaletta Bio, Inc.
- Cabaletta Bio Says US FDA Cleared Generalized Myasthenia Gravis Phase 1/2 Study of CABA-201